Evidence map›Paper›PMID 24876383›Full record

ArticleThe Journal of biological chemistry2014

Conserved allosteric hot spots in the transmembrane domains of cystic fibrosis transmembrane conductance regulator (CFTR) channels and multidrug resistance protein (MRP) pumps.

Shipeng Wei, Bryan C Roessler, Sylvain Chauvet, Jingyu Guo, John L Hartman, Kevin L Kirk

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Transformative therapies for rare CFTR missense alleles.Current opinion in pharmacology · 2017
    Review
  8. Molecular modelling and molecular dynamics of CFTR.Cellular and molecular life sciences : CMLS · 2017
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shipeng WeiFrom the Departments of Cell, Developmental, and Integrative Biology.
Bryan C RoesslerFrom the Departments of Cell, Developmental, and Integrative Biology.
Sylvain ChauvetFrom the Departments of Cell, Developmental, and Integrative Biology.
Jingyu GuoGenetics, and.
John L HartmanGenetics, and.
Kevin L KirkFrom the Departments of Cell, Developmental, and Integrative Biology, Neurobiology and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham Alabama 35294-0005 klkirk@uab.edu.
University of Alabama at Birmingham · US

Funding

Training Program in Cell, Molecular, and Developmental BiologyT32GM008111 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YODER, BRADLEY K. · 1985 to 2022
$5.4M
NEW PARADIGMS OF CFTR REGULATIONR01DK056796 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIRK, KEVIN L · 2000 to 2014
$3.9M
NIDDK NIH HHS R01 DK056796NIGMS NIH HHS T32 GM008111
6 · The paper itself

Abstract

ATP-binding cassette (ABC) transporters are an ancient family of transmembrane proteins that utilize ATPase activity to move substrates across cell membranes. The ABCC subfamily of the ABC transporters includes active drug exporters (the multidrug resistance proteins (MRPs)) and a unique ATP-gated ion channel (cystic fibrosis transmembrane conductance regulator (CFTR)). The CFTR channel shares gating principles with conventional ligand-gated ion channels, but the allosteric network that couples ATP binding at its nucleotide binding domains (NBDs) with conformational changes in its transmembrane helices (TMs) is poorly defined. It is also unclear whether the mechanisms that govern CFTR gating are conserved with the thermodynamically distinct MRPs. Here we report a new class of gain of function (GOF) mutation of a conserved proline at the base of the pore-lining TM6. Multiple substitutions of this proline promoted ATP-free CFTR activity and activation by the weak agonist, 5'-adenylyl-β,γ-imidodiphosphate (AMP-PNP). TM6 proline mutations exhibited additive GOF effects when combined with a previously reported GOF mutation located in an outer collar of TMs that surrounds the pore-lining TMs. Each TM substitution allosterically rescued the ATP sensitivity of CFTR gating when introduced into an NBD mutant with defective ATP binding. Both classes of GOF mutations also rescued defective drug export by a yeast MRP (Yor1p) with ATP binding defects in its NBDs. We conclude that the conserved TM6 proline helps set the energy barrier to both CFTR channel opening and MRP-mediated drug efflux and that CFTR channels and MRP pumps utilize similar allosteric mechanisms for coupling conformational changes in their translocation pathways to ATP binding at their NBDs.

Indexed as

Adenosine TriphosphateAdenylyl ImidodiphosphateAmino Acid SequenceAmino Acid SubstitutionATP-Binding Cassette, Sub-Family C ProteinsATP-Binding Cassette TransportersConserved SequenceCystic Fibrosis Transmembrane Conductance RegulatorHEK293 CellsHumansIon Channel GatingModels, MolecularMolecular Dynamics SimulationMolecular Sequence DataMutagenesis, Site-DirectedMutant ProteinsAdenosine TriphosphateAdenylyl ImidodiphosphateATP-Binding Cassette, Sub-Family C ProteinsATP-Binding Cassette TransportersCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorMutant ProteinsProlineRecombinant ProteinsSaccharomyces cerevisiae ProteinsYOR1 protein, S cerevisiaeABC TransporterAllosteric RegulationCystic FibrosisCystic Fibrosis Transmembrane Conductance Regulator (CFTR)Ion ChannelMolecular DynamicsMultidrug Transporter

Identifiers

PMID24876383
PMCPMC4106314
OpenAlexW2062753490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.